Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Revuforj® (revumenib) net product revenue in initial five weeks of launch –– Launched Niktimvo™ (axatilimab-csfr) in the U.S.

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant ... the trials to use MRD-negative CR and ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML ... settings by allowing the trials to use ...

The trial will assess MRD-negative complete response and event ... For ziftomenib, we expect to submit an NDA in relapsed/refractory NPM1-mutant AML in Q2, present top-line data for KOMET-001 ...

Kura Oncology Inc (KURA) reports significant revenue growth and strategic progress in its Q4 2024 earnings call, setting the stage for future developments.

Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential ... Submit an NDA for ziftomenib in R/R NPM1-m AML in the second ...